GT Biopharma (GT Biopharma) Days Sales Outstanding : 0.00 (As of Mar. 2024)

View and export this data going back to . Start your Free Trial

What is GT Biopharma Days Sales Outstanding?

GT Biopharma's average Accounts Receivable for the three months ended in Mar. 2024 was $0.00 Mil. GT Biopharma's Revenue for the three months ended in Mar. 2024 was $0.00 Mil.

The historical rank and industry rank for GT Biopharma's Days Sales Outstanding or its related term are showing as below:

During the past 13 years, GT Biopharma's highest Days Sales Outstanding was 239.34. The lowest was 239.34. And the median was 239.34.

GTBP's Days Sales Outstanding is not ranked ^*
in the Biotechnology industry.
Industry Median: 72.67
* Ranked among companies with meaningful Days Sales Outstanding only.

GT Biopharma's Days Sales Outstanding stayed the same from Mar. 2023 (0.00) to Mar. 2024 (0.00).

GT Biopharma Days Sales Outstanding Historical Data

The historical data trend for GT Biopharma's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GT Biopharma Days Sales Outstanding Chart

GT Biopharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Sales Outstanding

Get a 7-Day Free Trial

GT Biopharma Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Days Sales Outstanding	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of GT Biopharma's Days Sales Outstanding

For the Biotechnology subindustry, GT Biopharma's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

GT Biopharma's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GT Biopharma's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where GT Biopharma's Days Sales Outstanding falls into.

GT Biopharma Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

GT Biopharma's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

	Days Sales Outstanding (A: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (0	+	0)	/	1 )	/	0	*	365
=	0					/	0	*	365
=	N/A

GT Biopharma's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding (Q: Mar. 2024 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2023 )	+	Accounts Receivable (A: Mar. 2024 ))	/	count )	/	Revenue (A: Mar. 2024 )	*	Days in Period
=	( (0	+	0)	/	1 )	/	0	*	365 / 4
=	0					/	0	*	365 / 4
=	N/A

GT Biopharma (NAS:GTBP) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

GT Biopharma Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of GT Biopharma's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

GT Biopharma (GT Biopharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GT Biopharma Inc (NAS:GTBP) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

8000 Marina Boulevard, Suite 100, Brisbane, CA, USA, 94005

Website

https://www.gtbiopharma.com

GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.

Executives

Charles J Casamento	director	99 BELBROOK WAY, ATHERTON CA 94027
Michael Martin Breen	director, officer: Exec. Chair. and Interim CEO	LOWSLEY HOUSE 133 HEADLEY ROAD, LIPHOOK X0 GU30 7PU
Manu Ohri	officer: CFO & Secretary	2355 MAIN STREET, SUITE 120, IRVINE CA 92614
Bruce Wendel	director	70 ELEVEN O'CLOCK ROAD, WESTON CT 06883
Gregory Berk	officer: Pres. of R&D, CMO	HANA BIOSCIENCES, INC., 400 OYSTER POINT BLVD, SAN FRANCISCO CA 94080
Shrotriya Rajesh C Md	director	157 TECHNOLOGY DRIVE, IRVINE CA 92618
Alan Louis Urban	director	1524 CLOVERFIELD BOULEVARD, SUITE E, SANTA MONICA CA 90404
Gavin Choy	officer: Acting Chief Financial Officer	8000 MARINA BLVD, STE. 100, C/O GT BIOPHARMA, INC., BRISBANE CA 94005
Steven W Weldon	director, officer: CFO	7280 WESTPOINTE BLVD, APT 831, ORLANDO FL 32835
Shawn Cross	director, officer: Chief Executive Officer	1825 K STREET SUITE 510, WASHINGTON DC 20006
Raymond W. Urbanski	officer: Chief Medical Officer	28903 NORTH AVENUE PAINE, VALENCIA CA 91355
Kathleen Clarence-smith	director, 10 percent owner, officer: CEO	1623 31ST STREET NW, WASHINGTON DC 20007
Mark J Silverman	10 percent owner	224 22ND ST., SANTA MONICA CA 90402
Bristol Capital Llc	10 percent owner
Bristol Investment Fund Ltd	10 percent owner	89 NEXUS WAY, CAMANA BAY, PO BOX 311063, GRAND CAYMAN E9 KY1-1205